COMMUNIQUÉS West-GlobeNewswire

Daré Bioscience, Inc. to Present at the LD Micro 10th Annual Main Event Conference

04/12/2017 - 14:00

SAN DIEGO, Dec. 04, 2017 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE ), a healthcare company committed to the development and commercialization of innovative products in women’s reproductive health, today [...]

Zogenix Announces New Positive Efficacy and Safety Data from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome

04/12/2017 - 14:00

ZX008 Patients More Likely to Achieve Clinically Meaningful Reduction in Seizure Frequency Compared to Those on Placebo Parents/Caregivers and Investigators Rated Patients Treated with ZX008 as Very Much Improved or [...]

Oncolix, Inc. Expands Board of Directors with New Appointment

04/12/2017 - 13:30

HOUSTON, Dec. 04, 2017 (GLOBE NEWSWIRE) -- Oncolix, Inc. (OTC PINK:ONCX) (the “Company”), a biotechnology company focused on gynecological cancers, announced the appointment of John W. Holaday, Ph.D., to the Company’s [...]

Cutera Announces Appointment of Sandra Gardiner as CFO

04/12/2017 - 13:30

BRISBANE, Calif., Dec. 04, 2017 (GLOBE NEWSWIRE) -- Cutera, Inc. (NASDAQ: CUTR ) (“Cutera” or the “Company”), a leading provider of laser and energy-based aesthetic systems for practitioners worldwide, announced the [...]

Ultragenyx and Kyowa Kirin Announce Positive 48-Week Data from Adult Phase 3 Study of Burosumab (KRN23) in X-Linked Hypophosphatemia

04/12/2017 - 13:30

NOVATO, Calif. and TOKYO and LONDON, Dec. 04, 2017 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE ), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare [...]

ProMIS Neurosciences Announces Trading on OTCQB Venture Market

04/12/2017 - 13:30

TORONTO and CAMBRIDGE, Mass., Dec. 04, 2017 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc., a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced that [...]

Summit Therapeutics plc : Notice of Third Quarter Results

04/12/2017 - 13:01

Summit Therapeutics plc ("Summit" or the "Company") SUMMIT THERAPEUTICS TO REPORT FINANCIAL RESULTS FOR THE THIRD QUARTER AND NINE MONTHS ENDED 31 OCTOBER 2017 ON 6 DECEMBER 2017 Oxford, UK, 4 December 2017 - Summit [...]

BeyondSpring’s Lead Asset, Plinabulin, Recognized as 2017 National Science and Technology Major Project in China

04/12/2017 - 13:00

NEW YORK, Dec. 04, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI ), a global clinical stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced [...]

AzurRx BioPharma to Present at the Biotech Showcase 2018 Conference (January 8th)

04/12/2017 - 13:00

BROOKLYN, N.Y., Dec. 04, 2017 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX ) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal [...]

Resverlogix Closes Previously Announced $87 Million Private Placement with Shenzhen Hepalink

04/12/2017 - 13:00

CALGARY, Alberta, Dec. 04, 2017 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX ) announced today that it has closed its previously announced private placement of 60,416,667 equity units [...]

Summit Therapeutics to Report Financial Results for the Third Quarter and Nine Months Ended 31 October 2017 on 6 December 2017

04/12/2017 - 13:00

OXFORD, United Kingdom, Dec. 04, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ: SMMT ), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and [...]

GW Pharmaceuticals plc Reports Fiscal Fourth Quarter 2017 and Year-End Financial Results and Operational Progress

04/12/2017 - 13:00

- Epidiolex ® (cannabidiol) NDA Submitted to FDA - - Conference call today at 7:30 a.m. EST - LONDON and CARLSBAD, Calif., Dec. 04, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH ) (GW, the Company or the [...]

Nabriva Therapeutics Announces Completion of Enrollment in LEAP 2, a Phase 3 Clinical Trial Evaluating Oral Lefamulin for the Treatment of Community-Acquired Bacterial Pneumonia in Adults

04/12/2017 - 13:00

DUBLIN, Ireland and KING OF PRUSSIA, Pa., Dec. 04, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV ), a clinical stage biopharmaceutical company engaged in the research and development of novel anti- [...]

Loxo Oncology Announces Updated Larotrectinib Pediatric Clinical Trial Data Demonstrating Continued Durability of Response in TRK Fusion Cancers

04/12/2017 - 12:45

– 94 Percent of All Pediatric Patients Remain on Larotrectinib or Received Surgery with Curative Intent – – Larotrectinib Demonstrates Central Nervous System Activity with First-Ever TRK Fusion Glioblastoma Response [...]

The promoting mechanism of TRU NIAGEN™ to be featured at the American Academy of Anti-Aging Medicine World Congress

04/12/2017 - 12:30

IRVINE, Calif., Dec. 04, 2017 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ: CDXC ), a science-based, fully integrated nutraceutical company devoted to extending human healthspan, announced today it will feature its [...]

Novo Nordisk A/S - Share repurchase programme

04/12/2017 - 12:21

Bagsværd, Denmark, 4 December 2017 - On 1 November 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April [...]

Saniona AB: Saniona Selects Preclinical Candidate in GABAA a2/a3 Program for Neuropathic Pain and Chronic Itching

04/12/2017 - 08:01

PRESS RELEASE December 4, 2017 Saniona, a leading biotech company in the field of ion channels, today announces the selection of a preclinical candidate, SAN711, for the treatment of neuropathic pain and chronic itching [...]

Herantis Pharma Plc's financial reporting schedule and annual general meeting in 2018

04/12/2017 - 08:01

Herantis Pharma Plc's financial reporting schedule and annual general meeting in 2018 Herantis Pharma Plc. Company release 4 December 2017 at 9:00 am Herantis Pharma Plc ("Herantis") will publish its Financial [...]

Biophytis has FAMHP Approval to conduct SARA-INT phase 2b Interventional Study of Sarconeos in Sarcopenia in Belgium

04/12/2017 - 07:45

PARIS, Dec. 04, 2017 (GLOBE NEWSWIRE) -- BIOPHYTIS (Euronext Growth Paris:ALBPS), a biotechnology company specializing in the development of drug candidates to treat age-related diseases, today announces the approval [...]